-
Professors Jeremy Teoh and Yige Bao Share Research Highlights and Clinical Insights, as “Chinese Excellence” Shines on Europe’s Academic Stage
With diagnostic and therapeutic technologies advancing rapidly, precision treatment strategies for genitourinary malignancies such as urothelial carcinoma and prostate cancer are evolving with growing momentum. At the recent 2025 Annual Meeting of the European Association of Urology (EAU25), Professor Jeremy Teoh of The Chinese University of Hong Kong and Professor Yige Bao of West China…
-
SGBCC 2025 | Dr. Man Li: Chinese Innovation is Shaping Clinical Practice and Amplifying the Voice of China on the Global Stage
The 19th St. Gallen Breast Cancer Conference (SGBCC 2025) took place from March 12–15, 2025, in Vienna—the world-renowned capital of music. A major highlight of the event was the “Voice of China” session, where international experts gathered to exchange insights on the development of innovative therapies from China. On this occasion, Oncology Frontier sat down…
-
SGBCC Voice of China丨Dr. Yongmei Yin: Steady Progress Leads to Breakthroughs—Bridging East and West to Shape a New Era in Breast Cancer Care
The 19th St. Gallen Breast Cancer Conference (SGBCC 2025) recently concluded in Vienna, and once again, voices from China stood out on the global stage. Dr. Yongmei Yin from Jiangsu Provincial Hospital made history as the first Chinese female expert to join the St. Gallen International Consensus Panel on Early Breast Cancer, actively participating in…
-
Academician Binghe Xu: Lerociclib Ushers in a New Chapter for HR+/HER2− Advanced Breast Cancer Treatment
01 Current Landscape and Challenges in HR+/HER2− Breast Cancer: Clinical Use and Safety Considerations of CDK4/6 Inhibitors Oncology Frontier: CDK4/6 inhibitors have played an increasingly pivotal role in the treatment…
-
Dr. Lu Gan: Strategic Option of HDAC Inhibitors
The Evolution of Epigenetics and the Mechanism and Role of HDAC Inhibitors 1. The Evolution of Epigenetics Epigenetics is a subfield of genetics that studies heritable changes in gene expression…
-
Dr. Qingyuan Zhang: HDAC Inhibitors Offer Precise Epigenetic Regulation and Broader Treatment Options for Patients with HR+ Advanced Breast Cancer
Histone deacetylases (HDACs) are histone-modifying enzymes that play a key role in regulating epigenetic changes, and they are closely linked to the development and drug resistance of breast cancer. HDAC inhibitors (HDACis) can selectively modulate epigenetic features to control tumor cell proliferation, regulate the cell cycle, and repair DNA damage. As a representative class of…
-
Dr. Wenming Cao: Unraveling the Mechanistic Potential of HDAC Inhibitors in Overcoming Treatment Challenges in Breast Cancer
The normalization of epigenetic regulation has emerged as a promising therapeutic strategy in oncology. In hormone receptor-positive (HR⁺) breast cancer, the highly selective HDAC inhibitor (HDACi) entinostat has shown the ability to induce cell cycle arrest and apoptosis in multidrug-resistant tumor cells, addressing resistance to endocrine and targeted therapies at the mechanistic level. Moreover, a…
-
Prof. Zhaoqing Fan on the Role of Anthracycline-Free Regimens in HER2-Positive Breast Cancer: Insights from a China Multicenter Retrospective Study
Whether anthracyclines are essential in the neoadjuvant chemotherapy of HER2-positive breast cancer remains a long-debated question. The BCIRG-006 study suggested that anthracycline-containing and anthracycline-free regimens yielded numerically comparable survival outcomes, while the anthracycline-free TCbH regimen demonstrated a lower incidence of congestive heart failure and cardiac dysfunction. However, direct head-to-head comparisons between the two strategies are…
Connecting Medical Expertise through Media